American International Group, Inc. Adicet Bio, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.76 - $3.45 $19,736 - $38,688	11,214 Added 74.24%	26,319 $61,000
Q4 2023 Feb 13, 2024	SELL	$1.11 - $1.89 $68 - $117	-62 Reduced 0.41%	15,105 $28,000
Q3 2023 Nov 13, 2023	BUY	$1.37 - $3.4 $738 - $1,832	539 Added 3.68%	15,167 $20,000
Q2 2023 Aug 04, 2023	SELL	$2.13 - $7.13 $19 - $64	-9 Reduced 0.06%	14,628 $35,000
Q1 2023 May 12, 2023	BUY	$5.52 - $9.23 $1,611 - $2,695	292 Added 2.04%	14,637 $84,000
Q4 2022 Feb 10, 2023	BUY	$7.72 - $21.27 $7,025 - $19,355	910 Added 6.77%	14,345 $128,000
Q3 2022 Nov 14, 2022	BUY	$13.43 - $18.74 $2,538 - $3,541	189 Added 1.43%	13,435 $191,000
Q2 2022 Aug 12, 2022	BUY	$10.26 - $20.81 $4,688 - $9,510	457 Added 3.57%	13,246 $193,000
Q1 2022 May 13, 2022	BUY	$11.53 - $19.97 $19,312 - $33,449	1,675 Added 15.07%	12,789 $255,000
Q4 2021 Feb 11, 2022	SELL	$7.37 - $17.49 $2,454 - $5,824	-333 Reduced 2.91%	11,114 $194,000
Q3 2021 Nov 12, 2021	SELL	$6.29 - $9.93 $1,717 - $2,710	-273 Reduced 2.33%	11,447 $90,000
Q2 2021 Aug 13, 2021	BUY	$9.19 - $15.93 $107,706 - $186,699	11,720 New	11,720 $121,000

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $36M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.